MARKET

SNY

SNY

Sanofi FR
NASDAQ
37.25
-1.15
-2.99%
After Hours: 37.00 -0.25 -0.67% 18:57 09/26 EDT
OPEN
37.50
PREV CLOSE
38.40
HIGH
37.63
LOW
36.91
VOLUME
6.81M
TURNOVER
0
52 WEEK HIGH
57.79
52 WEEK LOW
36.91
MARKET CAP
93.27B
P/E (TTM)
13.52
1D
5D
1M
3M
1Y
5Y
Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors
The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.
Zacks · 4d ago
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer
Benzinga · 6d ago
Haleon rejects Zantac indemnification requests from GSK, Pfizer
Haleon rejects Zantac indemnification requests from GSK, Pfizer
Reuters · 6d ago
Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know
Sanofi (SNY) closed at $40.59 in the latest trading session, marking a -0.56% move from the prior day.
Zacks · 09/19 22:15
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
Benzinga · 09/19 19:03
Sanofi's rare blood disorder Enjaymo gets EMA panel nod for EU approval
A committee of the European Medicines Agency (EMA) recommended the approval of Sanofi's (NASDAQ:<a href=...
Seekingalpha · 09/16 12:54
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
Benzinga · 09/16 10:58
Sanofi Announced CHMP Recommended Approval of Beyfortus for Prevention of RSV Disease in Infants
The European Medicines Agency&#39;s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus® (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
Benzinga · 09/16 08:54
More
About SNY
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Webull offers kinds of Sanofi SA (ADR) stock information, including NASDAQ:SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.